The HOPE4MCI study: A randomized double-blind assessment of AGB101 for the treatment of MCI due to AD.

levetiracetam low dose (AGB101) - AgeneBio

http://www.ncbi.nlm.nih.gov/pubmed/38356475

Arnold Bakker; Marilyn S Albert; Michael Rosenblum; Michela Gallagher; Richard Mohs; Russell L Barton; Scott Zeger; Sharon Cohen; Sharon Rosenzweig-Lipson

Feb 15, 2024